PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
AdTech and Media$85.00-1.7%-15.0%SIRI 17,617 BBLR  2.741%IHRT -6.522%
Biotech$193.50-0.6%93.5%IBIO 3,930 IBIO  10.185%VXRT -5.074%
Cannabis$132.80-0.9%32.8%TLRY 35,796 HITI  8.496%LFLY -8.021%
Consumer Products$89.50-2.4%-10.5%PTON 14,303 DBI  1.805%PTON -14.45%
EV$77.70-2.2%-22.3%NKLA 96,329 EVGO  4.087%BEEM -9.704%
Global Health$102.50-0.4%2.5%ESPR 7,313 BCLI  9.489%VAXX -11.702%
Healthcare$86.001.2%-14.0%HIMS 7,796 NOTV  17.935%HIMS -4.462%
NextGen Tech & AI$90.50-1.5%-9.5%SOUN 62,292 EVLV  11.051%VHAI -15.498%
New Energy$88.600.1%-11.4%DNN 16,005 BE  15.629%LTBR -6.934%
MedDevices$91.30-0.4%-8.7%INMD 1,326 SSII  14.286%CTSO -7.076%
Mental Health$72.00-0.7%-28.0%TALK 1,507 BNOX  19.334%RVPH -15.584%
Oil & Gas$98.80-0.3%-1.2%SWN 13,708 KGEI  3.871%ICD -3.171%
Pharmaceuticals$76.401.9%-23.6%BDRX 2,957 BDRX  78.825%ATNM -7.172%
Psychedelics$113.60-0.7%13.6%CYBN 5,240 ITCI  2.955%GHRS -5.19%
Women’s Health$108.30-0.6%8.3%PDSB 959 PDSB  6.815%DARE -31.148%
Zombie$101.10-2.1%1.1%RIVN 48,469 FRPT  1.017%GME -7.209%

Prism View

Emerging AI Companies to Add To Your Watchlist as NVIDIA Reports Earnings Tomorrow

After the market closes tomorrow, NVIDIA Corporation (NVDA) will be announcing its Q1 financials, as investors look to laser their focus, on AI themes and insights from the Magnificent Seven, tech giant. Chip demand and the company’s investments into other…

Inside Look at Retail: Mixed Reports Across Multiple Industries as Earnings Season Slows – TGT, AZO, LOW, M

Despite headline news amping up for the big NVIDA Corp (NVDA) announcement tomorrow after the close, there have been some notable retail announcements contributing to this week’s tail end of earnings season. A good mix of retail companies have reported…

Prism Stocks making the biggest moves premarket: Macy’s, Lowe’s, Peloton, Zoom Video and more

Here are the top companies capturing attention in premarket trading: Macy's proved its mettle by gaining 3% on the back of sterling first-quarter earnings results and an upgraded outlook for the full year, thanks to a successful turnaround strategy. Lowe's…

As AI Utilization in Security Screening Broadens, PRISM AI Emerger Evolv (EVLV) is Taking Stake

While earnings season is wrapping up, there is still one name on everyone’s watchlist, NVIDIA Corporation…

BranchOut Food Achieves Record First Quarter

Leading food technology company, BranchOut Food Inc. (Nasdaq: BOF), has reported record financial results for the…

Prism Stocks making the biggest moves midday: Hims & Hers Health, Norwegian Cruise Line, Target and more

Unveil the companies that are making waves in the midday trading scene: Hims & Hers Health…

Prism Stocks making the biggest moves premarket: Apple, Nvidia, Li Auto and more

Here's a glimpse at the movers and shakers in the market before the opening bell. Apple…

PRISM New Energy Index Company Spruce Power (SPRU) Announces Q1 Earnings

Owner and operator of residential solar power, Spruce Power Holding Corp. (SPRU) announced earnings yesterday that…

Prism Stocks making the biggest moves premarket: GameStop, Reddit, Take-Two Interactive Software and more

Here are the headline-grabbing companies you should be aware of before the market opens: GameStop's shares…

Feature Story

What’s Next in the Great GLP-1 Race?

 Roche Holding (RHHBY) joined the race to commercialize its own GLP-1 (glucagon-like peptide-1) receptor agonist drug this week, announcing that its dual-agonist asset, CT-388, had achieved statistically significant weight loss in people with obesity in an early stage trial. At week 24 of treatment, 45% of participants achieved weight loss of approximately 20% of their body weight.

Competition in the weight loss field is fiercer than ever, as companies jostle to replicate the successes of Novo Nordisk (NOVO), the maker of Wegovy and Ozempic. To differentiate themselves from their competitors, many are focusing on developing more effective and longer-lasting formulations, preserving muscle during weight loss, and supporting weight management after GLP-1 drug dosing is discontinued. (more…)

Q&A Corner

Dr. Christopher Schaber, President and CEO

Soligenix: Building on Compelling Phase 3 Data with Accelerated Confirmatory Trial and Key Catalysts on the Horizon

 Late-stage biopharmaceutical company, Soligenix Inc (Nasdaq: SNGX) is advancing a broad pipeline of therapeutic and vaccine candidates across its two business segments, offering a diversified approach to drug development, and an attractive value proposition for investors.

Following success in its first Phase 3 clinical trial, which demonstrated statistical significance in its primary endpoint, the company’s lead product candidate, HyBryte™ (synthetic hypericin), will initiate a second confirmatory Phase 3 study in 2024 to replicate its findings from the first trial. HyBryte™, a promising treatment for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer, has been granted Orphan Drug Designations by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).  The FDA also has granted HyBryte™ Fast Track status.  The development progress to date, including the positive results in the first Phase 3 study, referred to as the FLASH (Fluorescent Light Activated Synthetic Hypericin) trial, potentially provides for a significantly de-risked path to regulatory approvals worldwide.

Alongside its strong biotherapeutics portfolio that includes two other active programs in psoriasis and Behçet’s disease, Soligenix has diversified its investment proposition with an established Public Health Solutions business. This segment of the company develops heat stable vaccines and therapeutics for military and civilian populations, using ThermoVax, its proprietary thermostabilization process which allows vaccines to be lyophilized (freeze-dried) while maintaining optimal potency – an important consideration in many locations around the world where cold chain logistics are not available.

Soligenix is addressing multiple attractive markets with the product candidates across its robust pipeline targeting potential commercial returns of ~$2B in global annual sales, another key value driver for investors.

PRISM MarketView spoke with Soligenix’s President and Chief Executive Officer, Dr. Christopher Schaber, to find out more about what investors can expect to see in 2024 and beyond.

Traders Lens

Larimar Therapeutics, Inc.

$LRMR which has been trading in a range between about $7 – $8.50 in the month of May, is up today after the FDA had removed a partial clinical hold on Larimar’s nomlabofusp clinical program yesterday after the close.

GT Biopharma, Inc.

Biotech company $GTBP is up over 100% as of now and has gapped right above its 50WMA on seemingly no major news. The company did release 1Q earnings last week on Wednesday the 15th.

AmpliTech Group, Inc.

$AMPG is the biggest loser in the Prism MarketView NextGen Tech index today and down 30% currently due to late filing concerns with the SEC as well as announcing it’s having problems with recovering 3.25 million in crypto investments that is being held by a potential fraudulent custodian.

Bio View

Lipella to Proceed with Phase 2b Clinical Trial in Hemorrhagic Cystitis

Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) has received Type C meeting guidance from the FDA regarding the design of its Phase 2b clinical trial. The FDA provided preliminary agreement on Lipella’s overall trial design, including objectives, safety monitoring,…

SS Innovations International (SSII) Furthers Market Penetration Strategy with 100th Cardiac Robotic Procedure

Surgical robotics company, SS Innovations International, Inc. (SSII) has announced a milestone for robotic cardiac surgery as its SSi Mantra Surgical Robotic System has surpassed its 100th cardiac surgery. The company who is dedicated to making world class robotic surgery…

NKGen to Progress Alzheimer’s Candidate into Phase 2; Shares Surge 75%

Shares in biotechnology company, NKGen Biotech (Nasdaq: NKGN) soared more than 75% in morning trading on Monday after the company announced that its lead candidate SNK01 has received Safety Review Committee clearance to progress into Phase 2 clinical development. The…

MIRA Pharmaceuticals Advances Potential First At-Home Ketamine Treatment for PTSD

MIRA Pharmaceuticals (Nasdaq: MIRA) is advancing closer to clinical development of what could potentially be the…

Moleculin Biotech Addresses Significant Unmet Need with Glioblastoma Trial

Pharmaceutical company, Moleculin Biotech (Nasdaq: MBRX), has initiated an Investigator-initiated Phase 2 study evaluating WP1066 in…

Soligenix Highlights Positive Clinical Results Published in Peer-Reviewed Dermatology Journal

Shares in late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX), climbed more than 7.0% on Thursday morning…

Biogen and Ionis to Terminate Development of ALS Candidate

In a setback to the ALS community, Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq:…
PRISM Indexes

AI startup Anthropic hires Airbnb veteran Krishna Rao as first CFO

Anthropic and Rao did not immediately respond to a Reuters request for comment.The company has raised billions from cloud service providers Google (NASDAQ:GOOGL) and… [Read More]